{
    "clinical_study": {
        "@rank": "41886", 
        "acronym": "EC-0701", 
        "arm_group": {
            "arm_group_label": "radiotherapy combined with chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Arm Label: radiotherapy combined with chemotherapy:\nRadiotherapy:\nPelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.\nCisplatin:\nTwo courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.\nCisplatin and Doxorubicin and Cyclophosphamide\uff1a Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.\nPaclitaxel and Carboplatin\uff1a Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
        }, 
        "brief_summary": {
            "textblock": "This phase II clinical trial was designed to assess the feasibility, safety, toxicity,\n      recurrence and survival pattern when TP or CAP chemotherapy was combined with adjuvant\n      radiation for patients with high-risk endometrial cancer."
        }, 
        "brief_title": "A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prosthesis Survival", 
        "condition_browse": {
            "mesh_term": [
                "Endometrial Neoplasms", 
                "Prosthesis Failure"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have had a hysterectomy (total abdominal, vaginal hysterectomy, or\n             laparoscopic-assisted vaginal hysterectomy) or modified radical hysterectomy or\n             radical hysterectomy and bilateral salpingo-oophorectomy no more than 8 weeks prior\n             to start of radiation therapy.\n\n        Additional surgical staging procedures are permissible but not required.\n\n          -  Risk factors: patients must fit one of the following:\n\n               -  Pelvic lymph node metastases\n\n               -  Paraaortic lymph node metastases\n\n               -  Grade 3 with myometrial invasion >50%\n\n               -  With stromal invasion of cervix\n\n               -  Known extrauterine disease (excluding second primary) confined to the pelvis.\n\n               -  High risk pathological type include: uterine papillary serous carcinoma, clear\n                  cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma,\n\n          -  No known gross residual disease, or distant metastases.\n\n          -  Eastern Cooperative Oncology Group (ECOG) score<=2; Age 18~75.\n\n          -  White Blood Cell (WBC)\u22654000/mm3, granulocytes \u22651500/mcl, platelets\u2265100,000/mcl.\n\n          -  Acceptable hepatic and renal function: creatinine <=1.4 mg%, bilirubin and serum\n             glutamate oxaloacetate transaminase (SGOT) <=2*normal.\n\n          -  No medical contraindications to chemotherapy, or radiation therapy.\n\n          -  Study-specific signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior pelvic radiation therapy.\n\n          -  Positive peritoneal cytology only for stage IIIa (FIGO 1998).\n\n          -  With history of other malignancies less than 5 years.\n\n          -  With gross residual disease, or distant metastases.\n\n          -  With endometrioid endometrial carcinoma and no risk factors:\n\n               -  with myometrial invasion <50%\n\n               -  Grade 1~2, with myometrial invasion >50%\n\n          -  With serious internal diseases which affect designed treatment\n\n          -  With psychotic disorders"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918124", 
            "org_study_id": "070148-7"
        }, 
        "intervention": [
            {
                "arm_group_label": "radiotherapy combined with chemotherapy", 
                "description": "Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.", 
                "intervention_name": "radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "radiotherapy combined with chemotherapy", 
                "description": "Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "radiotherapy combined with chemotherapy", 
                "description": "Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.", 
                "intervention_name": "Cisplatin and Doxorubicin and Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "radiotherapy combined with chemotherapy", 
                "description": "Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.", 
                "intervention_name": "Paclitaxel and Carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "disease free survival, overall survival", 
        "lastchanged_date": "August 6, 2013", 
        "link": {
            "url": "http://www.shca.org.cn"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200000"
                }, 
                "name": "Shanghai Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Clinical Trial of Adjuvant Postoperative Irradiation Combined With Paclitaxel/Carboplatin(TP) or Cisplatin/Doxorubicin/Cyclophosphamide (CAP) Chemotherapy for Patients With High-risk Endometrial Cancer", 
        "other_outcome": {
            "description": "Number of patients completed the treatment and number of patients with adverse events up to 5 years.", 
            "measure": "Number of patients with adverse events and number of patients completed the treatments", 
            "safety_issue": "Yes", 
            "time_frame": "up to 5 years"
        }, 
        "overall_official": {
            "affiliation": "Shanghai Cancer Center", 
            "last_name": "Huaying Wang, Doctor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "From date of randomization until the date of first documented progression, assessed up to 60 months.", 
            "measure": "Disease Free Survival(DFS)", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of first documented progression, assedded up to 60 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918124"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Fan Ming", 
            "investigator_title": "Shanghai Cancer Center", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "From date of randomization until the date of death from any cause, assessed up to 60 months.", 
            "measure": "Overall Survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of death from any cause, assedded up to 60 months."
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fan Ming", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}